Expression and Clinical Significance of S100A16 in Pancreatic Cancer
10.3971/j.issn.1000-8578.2021.21.0380
- VernacularTitle:钙结合蛋白S100A16在胰腺癌中的表达及临床意义
- Author:
Suyue ZHAO
1
;
Ling ZHANG
;
Ying ZHENG
;
Li YAO
;
Qianhe WANG
;
Xun LI
;
Kexiang ZHU
Author Information
1. The First Clinical Medical College, Lanzhou University, Lanzhou 730000, China
- Publication Type:Research Article
- Keywords:
Pancreatic cancer;
S100A16;
Immunohistochemistry;
Bioinformatics
- From:
Cancer Research on Prevention and Treatment
2021;48(12):1082-1086
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of S100A16 in pancreatic cancer and its clinical significance. Methods Immunohistochemical experiment was used to detect the expression of S100A16 protein in pancreatic cancer tissues and adjacent tissues, and we analyzed the relation between S100A16 positive expression and clinicopathological parameters, prognosis of pancreatic cancer patients. PPI was used to predict a protein relationship network that directly interacted with S100A16. Results The positive rate of S100A16 expression in cancer tissues was significantly higher than that in adjacent tissues (P=0.001). S100A16 expression was higher in patients with vascular infiltration and lymph node metastasis. The overall survival time of patients with pancreatic cancer was related to tumor size, TNM stage and S100A16 expression level. Multivariate analysis showed that the expression level of S100A16 was an independent risk factor for the prognosis of pancreatic cancer patients, and the risk of death in patients with high S100A16 expression increased by 1.5 times. PPI predicted that S100A16 and S100A14, IL36G, PITX1, PERP played an important role in the interaction network. Conclusion Pancreatic cancer patients with high S100A16 expression have poor prognosis. The positive expression of S100A16 is an independent prognostic indicator.
